Risks in the Drug Procurement System: Current Issues

Risks in the Drug Procurement System: Current Issues

##plugins.themes.bootstrap3.article.main##

Natalia Alekseevna PRODANOVA Plekhanov Russian University of Economics, Moscow, Russian Federation
Usman Salmanovich ZHAUBATYROV Astrakhan State Medical University 414000 121, Bakinskaya street, Astrakhan, Russian Federation
Elena Ivanovna ZATSARINNAYA Plekhanov Russian University of Economics, Moscow, Russian Federation
Vitaly V. GONCHAROV Kuban State Agrarian University named after I. T. Trubilin, Russian Federation
Nadezda Sergeevna ELIZAROVA Department «Personnel management»Moscow Polytechnic University, Russian Federation
Stepan Anatol'evich BURYAKOV Institute of Service and Entrepreneurship (branch) of the Federal State Budgetary Educational Institution of Higher Education "Don State Technical University" in Shakhty, Rostov Region. Russian Federation
Resumen

The public procurement segment is one of the components of the pharmaceutical market in Russia. Procurement of medicines and medical devices is the top sector of public procurement, both in terms of their number and the amount of contracts concluded. The procedure for concluding state contracts itself is spelled out in sufficient detail in the regulatory documents, but, despite this, risks may arise when concluding a state contract both for a potential applicant for a state order and for a state customer. The purpose of the study is to determine the possible risks when concluding a state contract of a healthcare institution for medicines and medical devices and ways to reduce them.

##plugins.themes.bootstrap3.article.details##

Citado por

Artículos más leídos del mismo autor/a


Sistema OJS - Metabiblioteca |